CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma.

ABSTRACT: We developed a computational pipeline designed to use RNA sequencing (n = 136) and gene expression profiling (n = 250) data from neuroblastoma tumors to identify cell surface proteins predicted to be highly expressed in MYCN amplified neuroblastomas and with little or no expression in normal human tissues. We then performed ChIP-seq in the MYCN amplified cell lines KELLY, NB-1643, and NGP to identify gene promoters that are occupied by MYCN protein to define the intersection with the differentially-expressed gene list. We initially identified 116 putative immunotherapy targets with predicted transmembrane domains, with the most significant differentially-expressed of these being the calmodulin kinase-like vesicle-associated gene (CAMKV, p = 2 × 10^-6<

SUBMITTER: Sussman RT 

PROVIDER: S-EPMC7069022 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature